Directory

• 2009
  Habilitation to Supervise Research (HDR) - University of Montpellier - France
• 1999
  PhD - Biochemistry & Molecular Biology - University of Montpellier - France
• 1995
  Master's degree - Health Biology - University of Montpellier - France

• 2023-
  Senior Researcher at INSERM, Institute of Functional Genomics (IGF) - Montpellier - France
• 2002-2022
  Junior Researcher at INSERM, Institute of Functional Genomics (IGF) - Montpellier - France
• 2000-2002
  Postdoctoral fellow, Institute of Interdisciplinary Research in Human and Molecular Biology (IRIBHM) - Brussels - Belgium

• Awards
• 2024-2026
  Research and Doctoral Supervision grant (PEDR)
• 2020-2023
  Research and Doctoral Supervision grant (PEDR)
• 2016
  Member of the Inserm cross-cutting Program Microbiota
• 2013
  Junior Faculty Award - AD/PD™ 2013 - The Alzheimer's & Parkinson's Conference
• 2012
  Chercheuse d'avenir 2011 of the Languedoc Roussillon Region
• 2011
  Soroptimist International (French Union) Medal
• 2010
  France Alzheimer Research prize 2010
• 1997
  Roche Bioscience Prize - Advances in Serotonin Receptor Research, San Francisco, USA

• Duties
• 2023-
  Neuroscience representative on the Board of the BioHealth Department of Univ. Montpellier
• 2015-2023
  Scientific Board member of France Alzheimer association
• 2005-2010
  Elected member of the IGF Unit Council
• 1997-
  Member of the International Society for Serotonin Research (ISSR)
• 1997-
  Member of the French Neuroscience Society

• Editing
• 2020-
  Associate editor for Frontiers in Aging Neuroscience,
• 2019-
  Review editor for F. in Neuroscience & F. in Endocrinology

• My areas of expertise cover neuropharmacology, G-protein coupled receptors (GPCRs), serotonin receptors and neurodegenerative diseases. In connection with a network of clinicians, chemists, and biotech companies I propose innovative strategies to cure Alzheimer's disease (α-secretase activation, Multi-Targeted drugs, biomarkers), based on a deep knowledge of molecular and cellular mechanisms induced by GPCRs in neuroprotection.

• Member of the Inserm cross-cutting Program Microbiota, I currently explore the potential of gut microbiota modulation as a new therapeutic avenue against Alzheimer's disease.